Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

0.29USD
16 Feb 2018
Change (% chg)

$-0.00 (-1.31%)
Prev Close
$0.29
Open
$0.30
Day's High
$0.30
Day's Low
$0.28
Volume
113,533
Avg. Vol
165,524
52-wk High
$1.05
52-wk Low
$0.25

Chart for

About

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $13.24
Shares Outstanding(Mil.): 46.07
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Auris Medical Holding AG Files For Resale Of Up To 7.5 Mln Common Shares Issuable Upon Exercise Of Certain Outstanding Warrants

* AURIS MEDICAL HOLDING AG FILES FOR RESALE OF UP TO 7.5 MILLION COMMON SHARES ISSUABLE UPON EXERCISE OF CERTAIN OUTSTANDING WARRANTS - SEC FILING Source text: [http://bit.ly/2BPfTod] Further company coverage:

Feb 09 2018

BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125

* AURIS MEDICAL REPORTS NEW DATA HIGHLIGHTING SUPERIOR BIOAVAILABILITY OF AM-125 COMPARED TO ORAL BETAHISTINE

Feb 07 2018

BRIEF-Auris Medical Announces Pricing Of $5.5 Mln Registered Direct Offering

* AURIS MEDICAL ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT OFFERING

Jan 29 2018

BRIEF-Auris Medical Announces Further Results From Healos Phase 3 Trial

* AURIS MEDICAL HOLDING AG SAYS ANNOUNCED FURTHER CLINICAL RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL, PROVIDES UPDATE ON AM-111 DEVELOPMENT PROGRAM

Jan 04 2018

UPDATE 2-Auris Medical shares plunge as deafness drug trial scrapped

* Shares plummet >50 pct to $0.38 (Adds background, details on Auris' pipeline; updates shares)

Nov 28 2017

BRIEF-Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness

* AURIS MEDICAL HOLDING AG SAYS ANNOUNCED TOP-LINE RESULTS FROM THE HEALOS PHASE 3 CLINICAL TRIAL OF AM-111 IN SEVERE TO PROFOUND SUDDEN DEAFNESS

Nov 28 2017

Auris Medical to abandon hearing-loss drug trial

Nov 28 Auris Medical Holding AG said on Tuesday it would terminate a late-stage study testing its drug to treat sudden deafness after the company's lead drug failed to improve hearing ability in patients in another study.

Nov 28 2017

BRIEF-Auris Medical Reports Q3 Loss Per Share CHF 0.14

* AURIS MEDICAL REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Nov 28 2017

BRIEF-Auris Medical Holding AG files for resale of up to 7.2 mln common shares

* Auris Medical Holding AG files for resale of up to 7.2 million common shares by selling shareholder, LPC Capital Fund Llc‍​ - SEC Filing Source text: (http://bit.ly/2ggfWjL) Further company coverage:

Oct 12 2017

BRIEF-Auris Medical announces share purchase agreements with Lincoln Park Capital Fund

* Auris Medical announces share purchase agreements with Lincoln Park Capital Fund, Llc

Oct 11 2017

Earnings vs. Estimates